Drug Profile
Research programme: antibacterials - Oscient Pharmaceuticals/Schering-Plough
Alternative Names: Staphylococcus aureus therapies - Oscient Pharmaceuticals/Schering-Plough; Antibacterials research programme - Oscient Pharmaceuticals/Schering-PloughLatest Information Update: 16 Nov 2009
Price :
$50
*
At a glance
- Originator Oscient Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 25 Oct 2007 This programme is still in active development
- 13 Apr 2004 Genome Therapeutics is now called Oscient Pharmaceuticals
- 12 Feb 2004 Genome Therapeutics has merged with GeneSoft Pharmaceuticals